Contribution of Neuroimaging to the Diagnosis of Alzheimer's Disease and Vascular Dementia

Archives of Medical Research

Volumn 43, Issue 8, 2012, Pages 671-676

  Román, Gustavo ^a   Pascual, Belén ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

Alzheimer's disease; Computerized tomography; Diffusion tensor imaging; Magnetic resonance imaging; Neuroimaging; Positron emission tomography; Single photon emission computerized tomography; Vascular dementia

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; FLORBETAPIR F 18; FLUORODEOXYGLUCOSE F 18; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE C 11; PITTSBURGH COMPOUND B; TAU PROTEIN;

ALZHEIMER DISEASE; BRAIN ATROPHY; BRAIN BLOOD FLOW; COMPUTER ASSISTED TOMOGRAPHY; CORTICAL THICKNESS (BRAIN); DIFFUSION TENSOR IMAGING; DISEASE COURSE; EARLY DIAGNOSIS; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GLUCOSE METABOLISM; HUMAN; MICROGLIA; MILD COGNITIVE IMPAIRMENT; MULTIINFARCT DEMENTIA; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POSITRON EMISSION TOMOGRAPHY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SPIN LABELING; WHITE MATTER;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ATROPHY; BIOLOGICAL MARKERS; BRAIN; DEMENTIA, VASCULAR; DIFFUSION TENSOR IMAGING; FUNCTIONAL NEUROIMAGING; HUMANS; INFLAMMATION; MAGNETIC RESONANCE IMAGING; NEUROIMAGING; POSITRON-EMISSION TOMOGRAPHY; TAU PROTEINS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84871664366     PISSN: 01884409     EISSN: 18735487     Source Type: Journal    
DOI: 10.1016/j.arcmed.2012.10.018     Document Type: Review

References (48)

1. Knopman D.S., DeKosky S.T., Cummings J.L., et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001, 56:1143-1153.
2. Filippi M., Agosta F., Barkhof F., et al. EFNS task force: the use of neuroimaging in the diagnosis of dementia. Eur J Neurol 2012, [Epub ahead of print].
3. Masdeu J.C., Pascual B. Neuroimaging of disorders leading to dementia. Curr Neurol Neurosci Rep 2008, 8:443-444.
4. Letourneau-Guillon L., Wada R., Kucharczyk W. Imaging of prion diseases. J Magn Reson Imaging 2012, 35:998-1012.
5. Scheltens P., Fox N., Barkhof F., et al. Structural magnetic resonance imaging in the practical assessment of dementia: beyond exclusion. Lancet Neurol 2002, 1:13-21.
6. Feinberg D.A., Moeller S., Smith S.M., et al. Multiplexed echo planar imaging for sub-second whole brain fMRI and Fast Diffusion Imaging. PLoS ONE 2010, 5:e15710.
7. Westman E., Wahlund L.O., Foy C., et al. Magnetic resonance imaging and magnetic resonance spectroscopy for detection of early Alzheimer's disease. J Alzheimer Dis 2011, 26:307-319.
8. Raji C.A., Lee C., Lopez O.L., et al. Initial experience in using continuous arterial spin-labeled MR imaging for early detection of Alzheimer disease. AJNR Am J Neuroradiol 2010, 31:847-855.
9. De Leon M.J., Ferris S.H., George A.E., et al. Computed tomography evaluations of brain-behavior relationships in senile dementia of the Alzheimer's type. Neurobiol Aging 1980, 1:69-79.
10. Apostolova L.G., Babakchanian S., Hwang K., et al. Ventricular enlargement and its clinical correlates in the imaging cohort from the ADCS MCI Donepezil / Vitamin E Study. Alzheimer Dis Assoc Disord 2012, [Epub ahead of print].
11. Kitagaki H., Mori E., Ishii K., et al. CSF spaces in idiopathic normal pressure hydrocephalus: morphology and volumetry. AJNR Am J Neuroradiol 1998, 19:1277-1284.
12. Braak H., Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 1991, 82:239-259.
13. Sassin I., Schultz C., Thal D.R., et al. Evolution of Alzheimer's disease-related cytoskeletal changes in the basal nucleus of Meynert. Acta Neuropathol (Berl) 2000, 100:259-269.
14. Nagy Z., Hindley N.J., Braak H., et al. Relationship between clinical and radiological diagnostic criteria for Alzheimer's disease and the extent of neuropathology as reflected by 'stages': a prospective study. Dement Geriatr Cogn Disord 1999, 10:109-114.
15. Kantarci K., Jack C.R. Neuroimaging in Alzheimer disease: an evidence-based review. Neuroimag Clin North Am 2003, 13:197-209.
16. Fox N.C., Warrington E.K., Freeborough P.A., et al. Presymptomatic hippocampal atrophy in Alzheimer's disease. A longitudinal MRI study. Brain 1996, 119:2001-2007.
17. Rombouts S.A., Barkhof F., Witter M.P., et al. Unbiased whole-brain analysis of gray matter loss in Alzheimer's disease. Neurosci Lett 2000, 285:231-233.
18. Juottonen K., Laakso M.P., Partanen K., et al. Comparative MR analysis of the entorhinal cortex and hippocampus in diagnosing Alzheimer disease. AJNR Am J Neuroradiol 1999, 20:139-144.
19. Xu Y., Jack C.R., O'Brien P.C., et al. Usefulness of MRI measures of entorhinal cortex versus hippocampus in AD. Neurology 2000, 54:1760-1767.
20. Thompson P.M., Mega M.S., Woods R.P., et al. Cortical change in Alzheimer's disease detected with a disease-specific population-based brain atlas. Cereb Cortex 2001, 11:1-16.
21. Wang L., Zang Y., He Y., et al. Changes in hippocampal connectivity in the early stages of Alzheimer's disease: evidence from resting state fMRI. Neuroimage 2006, 31:496-504.
22. Wattjes M.P. Structural MRI. Int Psychogeriatr 2011, 23(suppl 2):S13-S24.
23. Pasquier F., Leys D., Weerts J.G., et al. Inter- and intra-observer reproducibility of cerebral atrophy assessment on MRI scan with hemispheric infarcts. Eur Neurol 1996, 36:268-272.
24. Scheltens P., Leys D., Barkhof F., et al. Atrophy of medial temporal lobes on MRI in probable Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry 1992, 55:967-972.
25. Jagust W., Thisted R., Devous M.D., et al. SPECT perfusion imaging in the diagnosis of Alzheimer's disease. A clinical-pathologic study. Neurology 2001, 56:950-956.
26. Hoffman J.M., Welsh-Bohmer K.A., Hanson M.W., et al. FDG PET imaging in patients with pathologically verified dementia. J Nucl Med 2000, 41:1920-1928.
27. Shonk T.K., Moats R.A., Gifford P.G., et al. Probable Alzheimer's disease: diagnosis with proton MR spectroscopy. Radiology 1995, 195:65-72.
28. Bateman R.J., Xiong C., Benzinger T.L., et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012, 367:795-804.
29. Sperling R.A., Aisen P.S., Beckett L.A., et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011, 7:280-292.
30. Masdeu J.C., Kreisl W.C., Berman K.F. The neurobiology of Alzheimer disease defined by neuroimaging. Curr Opin Neurol 2012, 25:410-420.
31. Quigley H., Colloby S.J., O'Brien J.T. PET imaging of brain amyloid in dementia: a review. Int J Geriatr Psychiatry 2011, 26:991-999.
32. Small G.W., Kepe V., Ercoli L.M., et al. PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med 2006, 355:2652-2663.
33. Verhoeff N.P.L.G., Wilson A.A., Takeshita S., et al. In-vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET. Am J Geriatr Psychiatr 2004, 12:584-595.
34. Klunk W.E., Engler H., Nordberg A., et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004, 55:306-319.
35. Choi S.R., Schneider J.A., Bennett D.A., et al. Correlation of amyloid PET ligand florbetapir F 18 binding with Abeta aggregation and neuritic plaque deposition in postmortem brain tissue. Alzheimer Dis Assoc Disord 2012, 26:8-16.
36. Román G.C., Tatemichi T.K., Erkinjuntti T., et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993, 43:250-260.
37. Chabriat H., Levy C., Taillia H., et al. Patterns of MRI lesions in CADASIL. Neurology 1998, 51:452-457.
38. Chabriat H., Mrissa R., Levy C., et al. Brain stem MRI signal abnormalities in CADASIL. Stroke 1999, 30:457-459.
39. Guermazi A., Miaux Y., Rovira-Cañellas A., et al. Neuroradiological findings in vascular dementia. Neuroradiology 2007, 49:1-22.
40. Inzitari D., Pracucci G., Poggesi A., et al. Changes in white matter as determinant of global functional decline in older independent outpatients: three year follow-up of LADIS (LeukoAraiosis and DISability) study cohort. BMJ 2009, 339:b2477.
41. Fazekas F., Chawluk J.B., Alavi A., et al. MRI signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. AJNR Am J Neuroradiol 1987, 8:421-426.
42. Scheltens P., Barkhof F., Leys D., et al. A semiquantitative rating scale for the assessment of signal hyperintensities on magnetic resonance imaging. J Neurol Sci 1993, 114:7-12.
43. Vermeer S.E., Prins N.D., den Heijer T., et al. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 2003, 348:1215-1222.
44. Román G.C., Salloway S., Black S.E., et al. Randomized, placebo-controlled, clinical trial of donepezil in vascular dementia: differential effects by hippocampal size. Stroke 2010, 41:1213-1221.
45. Pascual B., Prieto E., Arbizu J., et al. Brain glucose metabolism in vascular white matter disease with dementia: differentiation from Alzheimer Disease. Stroke 2010, 41:2889-2893.
46. Tzourio C., Anderson C., Chapman N., et al. Effects of blood pressure lowering with perindipril and indamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 2003, 163:1069-1075.
47. Román G.C., Nash D.T., Fillit H. Translating current knowledge into dementia prevention. Alzheimer Dis Assoc Disord 2012, [Epub ahead of print].
48. Román G.C. Pathogenesis of cerebral small-vessel disease in obstructive sleep apnea. Sleep, Stroke, and Cardiovascular Disease, chapter 8 2013, 97-113. Cambridge University Press, New York. A. Culebras (Ed.).